Tag Archives: panel

RESI Boston Summer 2018 Panel Announcement: Corporate Venture Capital

24 May

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Reza Halse, President, MRL Ventures, this panel will feature:

By registering for RESI Boston, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

RESI on MaRS Panel Announcement: Diagnostics Investors

29 Mar

By Claire Jeong, Research Analyst, LSN

claire

The field of diagnostics can be a difficult space to navigate due to challenges in the regulatory and reimbursement processes that hinder successful commercialization. However, the implications of diagnostic technologies can be enormous; from precision genomics that enable optimum health management and personalized care to novel biomarkers that can successfully detect high mortality diseases in its earliest stages, diagnostics companies are developing some of the most highly disruptive technologies in the industry.

In this session, we invite 5 investors with strong expertise in this diverse space to speak about their unique approaches in working with early-stage companies. Investors will discuss the types of investment opportunities they seek and share valuable insights on building long lasting relationships, differentiating your technology from similar competitors, and more. We hope you will be able to join us for the RESI Toronto Conference in the MaRS Innovation Center on April 10th to meet these awesome panelists!

Moderated by Drew Taylor, Lead Medical Researcher, Epic Capital Management, the panel participants are:

  • Yiu-Lian Fong, Innovation Lead for Diagnostics, Johnson & Johnson (Medical Devices)
  • Kelly Holman, Co-Founder & Managing Director, Genesys Capital
  • Yvan Côté, General Manager of Dynacare Next & Orchid PRO-DNA, Dynacare
  • Amine Benmoussa, Principal (Healthcare), BDC Healthcare Fund

 

RESI on MaRS Panel Announcement: Corporate Venture Capital

22 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical and biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation – an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:

  • Marian Nakada, VP of Venture Investing, Johnson & Johnson
  • Jens Eckstein, President, SR One
  • Richard Osborn, Managing Partner, TELUS Ventures
  • Tom Gibbs, Director, Debiopharm Innovation Fund

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

%d bloggers like this: